Objectives: When tested in broth, avibactam reverses ceftazidime resistance in many Pseudomonas aeruginosa that express ESBLs. We examined whether similar reversal is observed against intracellular forms of P. aeruginosa. Results: For both extracellular and intracellular bacteria, ceftazidime C s was always close to its MIC. For ceftazidime-resistant strains, avibactam addition shifted ceftazidime C s to values close to the MIC of the combination in broth. E max was systematically below the detection limit (#5 log 10 ) for extracellular bacteria, but limited to #1.3 log 10 for intracellular bacteria (except for two isolates) with no effect of avibactam. The cellular concentration of avibactam reflected extracellular concentration and was not influenced by ceftazidime (0-160 mg/L).
Introduction
Pseudomonas aeruginosa, a major cause of nosocomial infections in immunocompromised or debilitated patients, is of concern to clinicians because of a high level of resistance in contemporary isolates through an array of mechanisms, among which constitutive and inducible expression of b-lactamases (including ESBLs and carbapenemases) play an important role.
1 P. aeruginosa is also able to enter, survive and even thrive in eukaryotic cells where the efficacy of most antibiotics is considerably reduced compared with what is observed against extracellular bacteria when tested in appropriate pharmacodynamic models. 2 Avibactam (formerly AVE1330A 3 and NXL104; 4, 5 see the recent review by Wang et al. 6 ) is a non-b-lactam ESBL inhibitor with activity against most class A and class C b-lactamases as well as some class D enzymes. 7, 8 In broth, avibactam fully reverses AmpC-and ESBL PER-1-mediated ceftazidime resistance in P. aeruginosa, 9,10 which translates to restoration of ceftazidime against this organism in wide-scale surveillance studies. [11] [12] [13] These results also show that avibactam reaches the bacterial periplasm and, therefore, crosses the outer membrane of P. aeruginosa.
Ceftazidime/avibactam has been approved in the USA for the treatment of complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and also for the treatment of complicated urinary tract infections (cUTI) in patients with limited or no alternative treatment options. 14 It has also been approved by the EMA for the treatment of adults with cIAI, cUTI (including pyelonephritis) or hospital-acquired pneumonia (including ventilator-associated pneumonia), and for the treatment of infections due to aerobic Gram-negative organisms in patients with limited treatment options. 15 Our aim was to examine whether avibactam restores ceftazidime activity against intracellular forms of b-lactamase-producing P. aeruginosa, which entails not only crossing the bacterial outer membrane but also the eukaryotic pericellular membrane and those of the intracellular vacuoles hosting the bacteria. 16 To this effect, we used a pharmacodynamic model originally developed in our laboratory for the quantitative study of the intracellular activity of antibiotics against phagocytosed Staphylococcus aureus 17 and validated for similar studies with P. aeruginosa. 16 We show here that, when tested against intracellular forms of P. aeruginosa that produce avibactam-inhibitable b-lactamase(s), avibactam restores ceftazidime activity to the same extent as in broth.
Materials and methods

Bacterial strains, susceptibility testing and genotypic detection of b-lactamases
The panel of strains assembled is shown in Table 1 . Two engineered strains with a basal non-inducible level of expression of AmpC (M1405 def and 2297 def) and their corresponding spontaneous mutants with stably derepressed constitutive hyperproducers of AmpC (M1405 CON and 2297 CON) were from Professor D. Livermore, 18, 19 and the clinical isolates with variable levels of susceptibility to ceftazidime from Belgian teaching hospitals. 20 Bacteria were grown in Mueller-Hinton broth and cfu counting was performed by plating serial dilutions on tryptic soy agar. MICs were measured according to the 2014 CLSI guidelines. 21 Detection of genes encoding known b-lactamases (see list in Table 1 ) was performed using a set of three multiplex endpoint PCR assays using appropriate primers. 22 
Materials
Avibactam sodium (potency 91.7%) and AZ13466915 were provided by AstraZeneca Pharmaceuticals (Waltham, MA, USA and Alderly Park, UK, respectively). Ceftazidime was obtained as Glazidim V R and gentamicin as Gentalline V R , the corresponding branded products for human parenteral use in Belgium and complying with the provisions of the European Pharmacopoeia. Colistin [sulphate salt (potency 67.5%)] was from SigmaAldrich, St Louis, MO, USA, levofloxacin (potency 95%) was from Aventis Pharma, Bad Soden, Germany and tobramycin [base (potency 95.8%)] was from Teva, Wilrijk, Belgium. Human serum was from Biowest SAS, Nuaillé, France, and cell culture media and FCS were from Gibco/Life Technologies Corporation (Paisley, UK). All other products were obtained from SigmaAldrich or Merck KGaA (Darmstadt, Germany).
Cells, cell culture and intracellular infection
Human THP-1 monocytes were cultivated as previously described 17 and intracellular infection was performed following a published protocol. 2, 16 In brief, bacteria were opsonized with 10% human serum in RPMI-1640 medium, phagocytosis was allowed for 2 h at a bacterium:cell ratio of 10:1 and non-phagocytosed bacteria were eliminated by incubation with gentamicin (100 mg/L, 60 min, 37 C) and three washes in PBS. The intracellular inoculum was typically 5-7 % 10 5 cfu/mg of cell protein. Ceftazidime was added to the medium [inoculated broth (10 6 cfu/mL) or cell culture medium of infected cells (see above)] at extracellular concentrations ranging from 0.01 to 200 mg/L alone or in combination with a fixed concentration of avibactam (4 mg/L, unless stated otherwise) to obtain a full concentration-response curve to the antibiotic. After 24 h of incubation at 37 C, samples were collected and treated as previously described. 16 In brief, for studies in broth, samples were serially diluted to enable viable counting and to minimize antibiotic carry-over, after which 50 lL of suspension was seeded on tryptic soy agar and colonies counted after 24 h of incubation at 37 C. For intracellular activity studies, cells were pelleted by low-speed centrifugation (1000 rpm, room temperature, 10 min), gently resuspended in PBS at 4 C, pelleted again (1000 rpm, 4 C, 10 min) to fully eliminate extracellular bacteria and minimize antibiotic carry-over, and resuspended in distilled water. After dilution, cell lysates were used for cfu counting by plating on tryptic soy agar and for measurement of total protein content by Lowry's assay (Bio-Rad DCTM Protein Assay, Bio-Rad Laboratories, Hercules, CA, USA). Both extracellular and intracellular activities were expressed as the change of cfu (per mL for studies in broth and per mg cell protein for studies in cells) from the initial inoculum (time 0) in log 10 units [ratio of post-treatment cfu to pre-treatment cfu, each expressed per mL (broth) or per mg cell protein (cells)]. Normalization for cellassociated cfu was made with respect to total cell protein rather than to cell numbers because our experience with the model was that a biochemical assay measuring total cell mass yielded more reliable and consistent results across successive experiments and conditions, partly due to the intrinsic variations associated with visual (microscopy) as well as automated cell counting methods.
Cellular penetration of avibactam
To assess the cellular penetration of avibactam, 10 7 THP-1 cells in a volume of 25 mL were incubated at 37 C with avibactam alone or combined with ceftazidime, pelleted (1300 rpm, 4 C, 7 min), washed twice in PBS at 4 C, resuspended in 200 lL of distilled water and sonicated to achieve homogenization (naked eye examination). AZ13466915, closely related to avibactam, was added to the samples at a final concentration of 1 mg/L as internal standard. A calibration curve was obtained from cell lysates spiked with increasing concentrations of avibactam and with 1 mg/L internal standard. Samples (100 lL) were mixed with 750 lL methanol/acetonitrile (4:21, v/v), vortexed for 1 min, kept at #20 C for 30 min and then centrifuged at 2500 rpm for 20 min. The supernatant was collected, dried under nitrogen and dissolved in 100 lL methanol/water (75: 25, v/v 
Curve fittings and statistical analyses
Curve fittings were performed with GraphPad Prism (version 7.02) using the Hill equation (sigmoidal dose response) with slope factor set to 1, and statistical analyses with GraphPad InStat 3.10, both for Windows (GraphPad Prism Software, San Diego, CA, USA).
Pharmacodynamic indices
The following pharmacodynamic indices were derived from data obtained from experiments examining concentration-effect relationships and to which the Hill equation could be fitted: E min and E max are the changes in cfu extrapolated for an infinitely low and infinitely large antibiotic concentration, respectively [minimal and maximal pharmacological effects of ceftazidime (minimal and maximal relative antibacterial efficacies in the model)]; C s is the concentration yielding no apparent change in cfu from the original inoculum [static effect (relative antibacterial potency in the model)]. 17 
Results
Susceptibility to ceftazidime and ceftazidime/avibactam Table 1 shows the MICs of ceftazidime and ceftazidime combined with a fixed concentration of avibactam (4 mg/L) for the reference and engineered strains and the clinical isolates. Based on ceftazidime MICs measured without and with avibactam, strains and isolates were assembled into three groups: group 1, those susceptible to ceftazidime (EUCAST interpretive criteria) for which the addition of avibactam had no effect [ATCC 27854, strains 2297 def and M1405 def and the parent strain 2297, and 12 clinical isolates (PAO1 was susceptible to ceftazidime but showed an MIC decrease from 8 to 2 mg/L with avibactam)]; group 2, those resistant to ceftazidime but made susceptible by addition of avibactam [strains 2297 CON and M1405 CON and 18 clinical isolates (which, when tested, proved also resistant to piperacillin/tazobactam); one isolate (PA119) showed a marked decrease in its MIC with avibactam but was still categorized as resistant based on the EUCAST ceftazidime susceptibility breakpoint]; and group 3, those resistant to ceftazidime and remaining resistant in the presence of avibactam (eight clinical isolates). All strains and isolates were susceptible to gentamicin, tobramycin, levofloxacin and colistin.
To ensure that a 4 mg/L concentration of avibactam was sufficient to fully restore the activity of ceftazidime in the strains and isolates intended for our experiments, we examined the effect of varying its concentration (from 0.03 to 128 mg/L) on ceftazidime MIC, using: (i) most strains and isolates from group 2; and (ii) selected isolates from groups 1 and 3 as controls. The results (see Figure S1 , available as Supplementary data at JAC Online) showed that the resistance of 12 out of the 18 isolates from group 2 plus the two engineered strains 2297 CON and M1405 CON was fully counteracted with 4 mg/L avibactam (no further decrease in ceftazidime MICs by increasing avibactam concentration). In contrast, 3 isolates from the same group (PA119, PA185, PA331) showed a further decease in ceftazidime MIC when the avibactam concentration was increased to .4 mg/L.
Extracellular and intracellular activity of ceftazidime/ avibactam against P. aeruginosa isolates with differing susceptibilities
Full 24 h ceftazidime concentration-response studies (aimed at determining and comparing the pharmacodynamic indices E min , E max and C s ) were performed using ceftazidime alone and ceftazidime combined with avibactam (4 mg/L) for six selected strains: (i) the ATCC 27853 reference strain; (ii) one clinical isolate (PA152) resistant to ceftazidime alone but susceptible when tested with avibactam; and (iii) the two engineered linked parent-daughter (isogenic) pairs M1405 def and 2297 def with basal AmpC 
Log 10 ceftazidime concentration (mg/L) Ceftazidime/avibactam and intracellular P. aeruginosa JAC expression (low MIC of ceftazidime) and their corresponding spontaneous mutants with stably derepressed AmpC (strains M1405 CON and 2297 CON; high MIC of ceftazidime). Results are shown in Figure 1 and Table 2 . Considering bacteria grown in broth first, all C s values were close to the corresponding MICs and all E max values below the actual limit of detection. Addition of avibactam did not change the response of ATCC 27853 to ceftazidime alone. In contrast, the situation drastically changed for PA152 for which the addition of avibactam caused a shift of the concentration-dependent curve to the left (becoming essentially similar to that of ATCC 27853), with: (i) a C s value close to the ceftazidime MIC for this isolate as measured in the presence of avibactam; and (ii) the lowest limit of detection observed at ceftazidime concentrations much lower than without avibactam and similar to those observed with ATCC 27853.
Moving now to intracellular bacteria, we see first that E max values for all strains were considerably smaller in magnitude (less negative; only #1 to #2 log 10 cfu compared with the original inoculum) than for bacteria in broth. E max of lower magnitude for intracellular bacteria compared with bacteria in broth have already been described for other b-lactams when tested with P. aeruginosa 16 and S. aureus in this model. 17, 25 With respect to C s , the values observed with ceftazidime or ceftazidime combined with avibactam were close to the corresponding MICs, indicating a marked increase in relative potency (lower C s values) caused by avibactam. In contrast, there was no change in intracellular E max values when combining avibactam with ceftazidime.
Examining now the results obtained with the engineered linked parent-daughter (isogenic) pairs of P. aeruginosa, we see that strains 2297 def and M1405 def showed results essentially similar to those seen previously with strain ATCC 27853. Thus, for bacteria in broth, a marked bactericidal effect of ceftazidime, with E max values below the lowest detection level, was achieved together with C s values close to the MIC of ceftazidime for the corresponding strains in broth. For intracellular bacteria, E max values of a much lower magnitude (i.e. less negative) were obtained but C s values were still close to the MIC of ceftazidime for the corresponding strains in broth. The addition of avibactam caused no meaningful change in the response of these strains to ceftazidime. For strains 6 Data are from the experiments shown graphically in Figure 2 and calculated from individual Hill-Langmuir functions (sigmoidal equations with slope factor " 1) fitted to each set of data (strains and conditions). Buyck et al.
2297 CON and M1405 CON, results were similar to those observed with PA152, i.e.: (i) E max values for bacteria in broth were below the lowest limit of detection, which was reached only at very large concentrations for 2297 CON (for M1405 CON, the extracellular concentration of ceftazidime could not be increased enough to obtain a bactericidal effect) with C s values close to the ceftazidime MIC; and (ii) a marked shift of the curves to the left upon addition of avibactam, making them essentially similar to those obtained with 2297 def and M1405 def. Avibactam, however, did not change in a meaningful way the E max values of either strain, which, for bacteria in broth, were below the lowest limit of detection, while reaching values of only #0.5 to #2 log 10 cfu only for intracellular bacteria.
The combined results for all strains and isolates shown in Figure 1 are shown graphically in Figure 2 as a function of multiples of their MIC, with the corresponding pertinent pharmacodynamic parameters presented in Table 3 . It clearly appears that: (i) all strains showed similar concentration-dependent curves when using equipotent concentrations of ceftazidime; (ii) an intense bactericidal effect (E max values close to the limit of detection) was globally obtained for the extracellular forms; (iii) conversely, the intracellular forms of all strains tested showed only a weak cfu decrease compared with the original, post-phagocytosis inoculum (E max at around #1 log 10 cfu); and (iv) that for both extracellular and intracellular forms, C s values were close to the MICs.
We expanded the study by examining additional clinical isolates from group 1 [PA128 and PA129 (susceptible to ceftazidime in the absence of avibactam and with no or only a minor decrease in MIC by addition of avibactam)], group 2 [PA27, PA65, PA139, PA156 and PA281 (full restoration of ceftazidime activity at a 4 mg/L avibactam concentration)] and group 3 [PA254 and PA258 (no restoration of ceftazidime by avibactam)]. The results essentially confirmed the data obtained so far, namely that: (i) intracellular E max values of ceftazidime for all isolates were limited to a maximum of #1.6 log 10 cfu (except for PA254 for which E max was #3.4 and #2.1 log 10 cfu when exposed to ceftazidime alone or to ceftazidime combined with avibactam, respectively); and (ii) C s values of ceftazidime against isolates for which avibactam reduced the MIC in broth were also shifted in a commensurate manner towards lower values upon addition of avibactam, while no meaningful change was seen for the isolates against which no effect of avibactam was seen in broth.
The impact of the addition of avibactam on the simultaneous decrease in the MIC and in the intracellular C s is shown graphically in Figure 3 for five laboratory strains and eight clinical isolates for which detailed data were available. In the absence of avibactam, most strains (except PA156 and PA139) were either with both an MIC and an intracellular C s 8 mg/L (n " 5) or with both an MIC and a C s above these values (n " 6). In the presence of avibactam, all but one strain (M1405 CON) had both an MIC and a C s 8 mg/L, indicating that avibactam restored the relative potency of ceftazidime to a similar extent whether acting on extracellular (broth) or intracellular P. aeruginosa.
Cellular penetration of avibactam
The penetration of avibactam in cells was assessed by comparing its total cellular concentration with its extracellular concentration in THP-1 monocytes after incubation with avibactam at two extracellular concentrations, in the presence of increasing concentrations of ceftazidime, and over time. Figure 4 shows that the concentration of avibactam in cells was consistently close to its extracellular concentration, without any statistically significant influence being exerted by its own concentration (4 or 10 mg/L) or by the presence of ceftazidime (0-160 mg/L), and with an apparent equilibrium achieved within 2 h.
Discussion
The present study extends our knowledge of the properties of avibactam by showing restoration of the activity of ceftazidime against b-lactamase-producing P. aeruginosa when bacteria are phagocytosed and thrive intracellularly. We used a validated pharmacodynamic model already applied to the study of a large number of approved and experimental antibiotics when acting against Ceftazidime/avibactam and intracellular P. aeruginosa JAC intracellular bacteria. 2 The data may have both pharmacological and clinical significance.
Examining the data in a pharmacological context, we see first that addition of avibactam to ceftazidime in the extracellular medium resulted in phagocytosed bacteria behaving essentially like fully susceptible ones with respect to the extracellular concentration needed to obtain a static effect (C s , relative potency). Also, comparing ceftazidime potencies between extracellular and intracellular bacteria on the one hand, and ceftazidime/avibactam potencies likewise on the other, leads us to suggest that avibactam is able to freely enter THP-1 monocytes and reach b-lactamases present in the intermembrane space of phagocytosed bacteria in an unhindered fashion compared with bacteria in broth. Avibactam is expected to be negatively charged at pH 5-8 (based on Reaxys V R version 2.20770.1, www.reaxys.com), which should prevent it from accumulating in cells. 26 Yet, the direct measurement of its penetration into THP-1 monocytes shows an apparent total concentration reflecting almost exactly its extracellular one. The data were also Table 3 . Pertinent regression parameters and goodness of fit of the 24 h dose-response curves of ceftazidime alone (CAZ) and of ceftazidime combined with avibactam at a fixed concentration (4 mg/L; CAZ/AVI) for extracellular (broth) and intracellular (THP-1 cells) activity of ceftazidime when pooling data from all strains presented individually in Figure 2 (ATCC 27853, PA152, PA315, M1405 def, M1405 CON, 2297 def and 2297 CON) as shown collectively, and normalized by MIC, in Figure 3 Activity Condition E min a (D log 10 cfu) (CI) Table 1 ) and the corresponding apparent static concentrations (C s ) of ceftazidime (ordinate) against their intracellular forms [MIC data are from Table 1 and C s values are from Table 2 . The vertical broken line shows the EUCAST breakpoint for ceftazidime (resistance is greater than this limit) and the horizontal broken line shows the same value for C s .
consistent with ceftazidime being able to reach its intracellular target as it does it for bacteria in broth. This was actually already observed for other b-lactams when tested against phagocytosed P. aeruginosa, 16 and was also observed for many other antibiotics for the same bacteria 16 as well as for S. aureus 17, 25, 27, 28 (see also Buyck et al. ). A marked exception, however, was seen for aminoglycosides for which intracellular potencies were lower than in broth (C s values higher than MICs), due probably to the defeating effect exerted by the low pH prevailing in the phagolysosomes on the activity of these antibiotics (see discussion in Tulkens and Trouet
23
) and demonstrating the ability of the model to apprehend such differences.
A second pharmacological observation is that the intracellular maximal relative effect of ceftazidime (E max , maximal relative efficacy in the model), even in the presence of avibactam, was only a minor fraction of what can be observed in broth. Once again, this has been observed quite systematically when assessing the activity of many different antibiotics, and especially b-lactams. 16, 25 It is important to emphasize that E max values are extrapolated values for an infinitely large extracellular antibiotic concentration, corresponding to the maximal effect (and, therefore maximal efficacy in the model) that can be obtained with the antibiotic even when pushed beyond the highest tested concentration (assuming that the function describing the antibiotic concentration-effect relationship remains the same as the one fitted to the actual data). Thus, ceftazidime (with or without avibactam), as many other antibiotics (see Van Bambeke and Tulkens 29 for a list of examples), appears unable to eradicate phagocytosed bacteria not through lack of potency (as discussed above) but because of lack of efficacy. Thus, part of the intracellular inoculum may not respond to the presence of the antibiotic (discussed in Buyck et al., 2 Van Bambeke and Tulkens 29 and Van Bambeke et al.
30
), which may explain the relapsing and recurrent character of the infections where the intracellular inoculum represents an important part of the bacterial load (see examples in Shigeoka and Hill 31 and Bayston et al. 32 and in Drilling et al. 33 and Hamza et al. 34 for P. aeruginosa and S. aureus, respectively).
Moving now to the clinical significance of our data, they clearly indicate that intracellular inocula of bacteria producing b-lactamases are no more protected from avibactam than bacteria in broth. This is reassuring as the main indications for which ceftazidime/avibactam is approved may entail substantial intracellular inocula, due to phagocytosis of the offending organisms in lung and peritoneal macrophages [35] [36] [37] as well as urinary tract cells. 38 This supports using avibactam to restore ceftazidime activity in these approved indications. More broadly speaking, our studies call for similar investigations with already approved as well as with other novel b-lactamase inhibitors to see how they compare with avibactam for restoring susceptibility to intracellular forms of P. aeruginosa and other Gram-negative bacteria when these produce b-lactamase(s).
The present study has several limitations. First, we do not know what the subcellular distribution of avibactam is and have not directly assessed its assumed binding to and inactivation in situ of the b-lactamases produced by P. aeruginosa in phagocytes. This would require detailed drug disposition and metabolic studies in both non-infected and infected cells. The model also explores only one time point (24 h) due to intrinsic limitations (lack of growth before 8-10 h; explosive growth after 30 h in the absence of antibiotics) discussed previously. 2, 16 The model is also a pharmacological one assessing the intracellular activity of antibiotics but not the cooperation between host cells and antibiotics, as unstimulated THP-1 monocytes show rather weak defences against invading bacteria (see discussion in Carryn et al.
39
). Next, the intracellular concentrations of ceftazidime were not measured, but we know that b-lactams, generally speaking, do not accumulate in eukaryotic cells and rather tend to reach cell concentrations similar to the extracellular ones. 23, 30 Our data also show that a fixed concentration of avibactam of 4 mg/L may be insufficient to completely inhibit the activity of b-lactamase(s) of some P. aeruginosa clinical isolates encountered in the hospital from which they were collected. This was also observed among a small number of ceftazidime-resistant isolates of P. aeruginosa selected by others for in vivo Ceftazidime/avibactam and intracellular P. aeruginosa JAC pharmacodynamics studies. 40 Our study, however, was neither designed nor powered as a true epidemiological survey since the isolates were selected for study based on their retrospectively known special phenotypic properties. The data must therefore be considered only as indicative. We note that similar in vitro observations have also been made for the combination of avibactam with aztreonam, 41 suggesting that detailed efficacy studies may be of interest. Lastly, we only examined one bacterial species, one b-lactam and one b-lactamase inhibitor, which means that the results cannot be extrapolated to other Gram-negative b-lactamase-producing bacteria or to other b-lactam-b-lactamase inhibitor combinations. This could be addressed in the future using the tools reported here. Figure S1 is available as Supplementary data at JAC Online (https://aca demic.oup.com/jac).
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